ReliaTech 廣州鴻程代理

ReliaTech 廣州鴻程代理

ReliaTech GmbH（Receptor Ligand Technologies GmbH 的簡稱）是一家成立于 1999 年的德國后基因組生物技術公司。除其他研究產品外，該公司還開發、生產和銷售用于血管生成和淋巴管生成研究的高質量研究試劑。

作為一家擁有自己內部試劑生產的公司，ReliaTech GmbH 還為客戶特定的試劑生產提供解決方案。我們在蛋白質純化方面的豐富經驗和我們在日常實驗室業務中的實踐知識也融入了我們以客戶為基礎的項目——使我們成為需要個性化生產解決方案的項目的有力合作伙伴。

Receptor Ligand Technologies GmbH公司（RELIA Tech）位于德國不倫瑞克，是一家后基因組生物技術公司，該公司運用*技術專注于受體和配體的發現與研究，并使之商業化，產品廣泛用于科學研究、實驗診斷和臨床應用。RELIA Tech的靈活性和競爭力必將使其在這個快速整合的功能基因組學和蛋白組學的新時代發展壯大。RELIA公司提供的細胞因子、生長因子、重組蛋白產品均有內毒素檢測項目，且內毒素水平非常低。

Receptor Ligand Technologies GmbH (RELIATech) is a post-genomic biotechnology company focused on the discovery and commercialisation of novel technologies and products in the field of ligand-receptor interaction for research, diagnostics and for the clinical community. The company located in Braunschweig, Germany, was founded in October 2000 by:

Prof. Avner Yayon

Weizmann Institute of Science (WIS), Israel

Dr. Herbert A. Weich

German Research Centre for Biotechnology (GBF), Germany

Dr. Bernhard Barleon

Clinic for Tumor Biology (KTB), Germany

The founders are cell and molecular biologists working in the field of growth factor interaction, tyrosine kinases and their signalling pathways involved in tissue remodelling, homeostasis and disease for more than 1 decade. In particular Dr. Herbert A. Weich and Dr. Bernhard Barleon have worked in basic research in the field of angiogenesis, tumor angiogenesis and the progression of solid tumors.   

Signal proteins such as "growth factors and cytokines", together with their transmembrane / "soluble receptors" and associated kinases, are critically involved in the development and function of all higher organisms as key regulatory molecules in physiological and pathophysioloical conditions. These polypeptides regulate cell differentiation, tissue remodelling and homeostasis, and are deregulated in various disease states. The discovery of new growth-regulating genes by the human genome project coding for novel signaling proteins, together with the elucidation of their function, will no doubt be one of the major challenges in the next decade.

RELIATech’s mission is the development and commercialisation of new products useful in the field of "receptor and ligand interaction" for basic research, drug development and for the clinical community. RELIATech’s flexibility and competence will definitely enable its rapid integration and expansion in this new era of functional genomics and proteomics.